Clinical Trial of Tripterygium Wilfordii Hook F. in Human Kidney Transplantation in China
- 1 June 2006
- journal article
- research article
- Published by Elsevier BV in Transplantation Proceedings
- Vol. 38 (5), 1274-1279
- https://doi.org/10.1016/j.transproceed.2006.03.017
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Early versus late acute rejection episodes in renal transplantationTransplantation, 2003
- Triptolide is a potent suppressant of C3, CD40 and B7h expression in activated human proximal tubular epithelial cellsKidney International, 2002
- Why do kidney grafts fail?. A long-term single-center experienceTransplant International, 2002
- PG490-88, a Derivative of Triptolide, Blocks Bleomycin-Induced Lung FibrosisThe American Journal of Pathology, 2001
- IMMUNOSUPPRESSIVE ACTIVITY OF THE CHINESE MEDICINAL PLANT TRIPTERYGIUM WILFORDIITransplantation, 2000
- The Banff 97 working classification of renal allograft pathologyKidney International, 1999
- Isolation, purification, and characterization of immunosuppressive compounds from tripterygium: Triptolide and tripdiolideInternational Journal of Immunopharmacology, 1995
- Triptolide suppresses T-lymphocyte proliferation by inhibiting interleukin-2 receptor expression, but spares interleukin-2 production and mRNA expressionInternational Journal of Immunopharmacology, 1994
- THE INCIDENCE AND IMPACT OF EARLY REJECTION EPISODES ON GRAFT OUTCOME IN RECIPIENTS OF FIRST CADAVER KIDNEY TRANSPLANTSTransplantation, 1992
- Prolonged survival of MRL-lpr/lpr mice treated with Tripterygium Wilfordii Hook-FClinical Immunology and Immunopathology, 1992